SEC Form 4 · accession 0001127602-18-035081
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alane P Barnes
Officer — Senior VP, Chief Legal Officer
Period of report
Nov 30, 2018
Accepted (ET)
Dec 4, 2018 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2018 | M | 25,000 | $1.42 | A | 122,243 | D | |
| Common StockF1 | Nov 30, 2018 | S | 44,290 | $9.07 | D | 77,953 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $1.42 | Nov 30, 2018 | M | 25,000 | D | Jan 1, 2014 | Jan 1, 2023 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.00 to $9.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.